LONDON (Reuters) - AstraZeneca may not stay in the vaccine business in the long run and is looking to buy small and mid-sized companies specialising i.
Asked about inflationary pressures, Soriot said: "We are going to have to become more innovative and productive. We can't expect our selling prices to go up."
AstraZeneca vaccine shows 74% efficacy in large U S -backed trial, and BioNTech co-founder says COVID will become manageable morningstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from morningstar.com Daily Mail and Mail on Sunday newspapers.
AstraZeneca boss Soriot says do not rush needlessly into COVID booster vaccines -The Telegraph reuters.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from reuters.com Daily Mail and Mail on Sunday newspapers.